Bernstein Initiates Coverage On Summit Therapeutics with Underperform Rating, Announces Price Target of $7.7

Benzinga Newsdesk www.benzinga.com Neutral 53.5%

Neg 0% Neu 53.5% Pos 0%

Bernstein analyst Jeffrey Walch initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underperform rating and announces Price Target of $7.7.